Company Overview of Celyad SA
Celyad SA, a biopharmaceutical company, focuses on engineered cell therapy treatments. It operates in two segments, Cardiology and Immuno-oncology. The company’s lead product candidate in cardiovascular disease is C-Cure, an autologous cell therapy for the treatment of patients with ischemic heart failure. Its lead product candidate in oncology disease is CAR-T NKR-2, an autologous chimeric antigen receptor (CAR) for the treatment of cancer. In addition, the company’s preclinical stage product candidates include NKp30, an activated receptor of NK cells; B7H6 therapies, which kills cancer cells; and CAR T-cell, an allogeneic T-cell platform. Further, it offers C-CATHez, a cell injection cathe...
Axis Business Park
Rue Edouard Belin 12
Founded in 2004
Key Executives for Celyad SA
Chief Executive Officer and Executive Director
Total Annual Compensation: €562.0K
Compensation as of Fiscal Year 2016.
Celyad SA Key Developments
Celyad Initiates Second Dose Escalation in THINK Trial in First US Patient
Apr 28 17
Celyad announced the dosing of the first patient of the second dose in the solid tumor arm of its THINK trial (THerapeutic Immunotherapy with NKR-2). This first ovarian cancer patient has been dosed at Roswell Park Cancer Institute (Buffalo, New York). At the first solid tumor dose-level, one pancreatic and two colorectal cancer patients were successfully dosed. None of these patients experienced dose limiting adverse events. THINK is a multinational open-label Phase I study to assess the safety and clinical activity of multiple administrations of autologous NKR-2 T-cells in seven refractory cancers including five solid tumors (colorectal, ovarian, bladder, triple-negative breast and pancreatic cancers) and two hematological tumors (acute myeloid leukemia and multiple myeloma). These cancer indications were selected based on strong preclinical evidence and NKG2D ligand expression. The THINK trial is being conducted in the US and in Europe. It contains a dose escalation and an extension stage. The dose escalation is conducted in parallel in the solid and liquid cancer groups, while the extension phase will evaluate in parallel each tumor independently. The dose escalation design includes three dose levels adjusted to body weight: up to 3x108, 1x109 and 3x109 NKR-2 T-cells. At each dose, the patients receive three successive administrations, two weeks apart, of NKR-2 T-cells at the specified dose.
Celyad SA Presents at 10th Kempen & Co Life Sciences Conference, Apr-19-2017
Apr 5 17
Celyad SA Presents at 10th Kempen & Co Life Sciences Conference, Apr-19-2017 . Venue: Kempen & Co Offices, Beethovenstraat 300, Amsterdam, Netherlands.
Celyad SA Announces Consolidated Earnings Results for the Year Ended December 31, 2016
Mar 23 17
Celyad SA announced consolidated earnings results for the year ended December 31, 2016. For the period, the company’s revenue was EUR 8,523,000 as compared to EUR 3,000 for the same period last year. Loss before taxes was EUR 23,612,000 as compared to EUR 29,114,000 for the same period last year. Loss for the year was EUR 23,606,000 as compared to EUR 29,114,000 for the same period last year. Basic and diluted loss per share was EUR 2.53 as compared to EUR 3.43 for the same period last year. Net cash used in operations was EUR 24,692,000 as compared to EUR 27,303,000 for the same period last year. Operating loss was EUR 25,609,000 against EUR 29,672,000 reported last year. Acquisitions of property, plant and equipment was EUR 1,687,000 against EUR 811,000 reported last year.
Similar Private Companies By Industry
Recent Private Companies Transactions